{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:07:28Z","timestamp":1783156048463,"version":"3.54.6"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/rlu.0b013e31825b2583","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T10:35:44Z","timestamp":1342002944000},"page":"e184-e188","source":"Crossref","is-referenced-by-count":51,"title":["Revisiting the Clinical Value of 18F-FDG PET\/CT in Detection of Recurrent Epithelial Ovarian Carcinomas"],"prefix":"10.1097","volume":"37","author":[{"given":"Lidija","family":"Antunovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Cimitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Borsatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Baresic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Giorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Steffan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Balestreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Rubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Canzonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20210204","first-page":"1233","article-title":"Ovarian cancer: risk of recurrence by stage of diagnosis.","volume":"101","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R2-31-20210204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":". Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R3-31-20210204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejogrb.2003.10.029","article-title":". Post-therapy surveillance and after-care in ovarian cancer.","volume":"114","author":"Von Georgi","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R4-31-20210204","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1371\/journal.pmed.0050232","article-title":". Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.","volume":"5","author":"Kobel","year":"2008","journal-title":"PLoS Med"},{"key":"R5-31-20210204","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R6-31-20210204","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3322\/canjclin.49.5.297","article-title":"Epithelial ovarian cancer: prevention, diagnosis, and treatment.","volume":"49","author":"Partridge","year":"1999","journal-title":"CA Cancer J Clin"},{"key":"R7-31-20210204","first-page":"2012","article-title":"ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer ACR Web site. Reston, VA: American College of Radiology; 2009. Available at: .","author":"Javitt","year":"16","journal-title":"Accessed January"},{"key":"R8-31-20210204","first-page":"2012","article-title":"PET Imaging in Ovarian Cancer: Recommendations. A Quality Initiative of Program in Evidence-Based Care Cancer Care Ontario (CCO) Web site. Ontario, Canada: Cancer Care Ontario; 2009. Available at: .","author":"Prefontaine","year":"16","journal-title":"Accessed January"},{"key":"R9-31-20210204","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ygyno.2004.12.007","article-title":". FDG-PET for management of cervical and ovarian cancer.","volume":"97","author":"Havrilesky","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R10-31-20210204","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":". CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis.","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"key":"R11-31-20210204","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00066-004-1208-3","article-title":". The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer.","volume":"180","author":"Menzel","year":"2004","journal-title":"Strahlenther Onkol"},{"key":"R12-31-20210204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10147-005-0489-6","article-title":". Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.","volume":"10","author":"Takekuma","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"R13-31-20210204","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MNM.0b013e32831089cb","article-title":". 18F-FDG PETCT evaluation of patients with ovarian carcinoma.","volume":"29","author":"Iagaru","year":"2008","journal-title":"Nucl Med Commun"},{"key":"R14-31-20210204","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00259-007-0366-9","article-title":". Diagnostic accuracy of FDG PET in the follow up of platinum-sensitive epithelial ovarian carcinoma.","volume":"34","author":"Garcia-Velloso","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-31-20210204","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00404-010-1404-6","article-title":". Combined positron emission tomography computed tomography and tumor markers for detecting recurrent ovarian cancer.","volume":"283","author":"Pan","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R16-31-20210204","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00404-010-1568-0","article-title":". Impact of positron emission tomographycomputed tomography in the management of patients with epithelial ovarian carcinoma after treatment.","volume":"283","author":"Nasu","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R17-31-20210204","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/IGC.0b013e3181e82a7f","article-title":". Clinical utility of positron emission tomographycomputed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.","volume":"20","author":"Bhosale","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"R18-31-20210204","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":". Integrated PETCT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.","volume":"34","author":"Mangili","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-31-20210204","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2007.07.082","article-title":". Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.","volume":"108","author":"Soussan","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R20-31-20210204","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","article-title":". The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project.","volume":"112","author":"Fulham","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R21-31-20210204","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1525-1438.2005.00245.x","article-title":"Positron emission tomography application for gynecologic tumors.","volume":"15","author":"Nakamoto","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R22-31-20210204","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2005.02.029","article-title":". (18)F-FDG PETCT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.","volume":"31","author":"Nanni","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"R23-31-20210204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2214\/ajr.177.1.1770123","article-title":". Preoperative diagnosis of ovarian tumors with MR imaging comparison with transvaginal sonography, positron emission tomography, and histologic findings.","volume":"177","author":"Rieber","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"R24-31-20210204","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2214\/ajr.174.4.1741005","article-title":". FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features.","volume":"174","author":"Berger","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"R25-31-20210204","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00259-001-0750-9","article-title":". Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose.","volume":"29","author":"Torizuka","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-31-20210204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11307-010-0468-9","article-title":". Value of FDG PETCT in patients with treated ovarian cancer and raised CA125 serum levels.","volume":"14","author":"Palomar","year":"2012","journal-title":"Mol Imaging Biol"},{"key":"R27-31-20210204","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/RLU.0b013e318219b523","article-title":". Noninvasive and invasive staging of ovarian cancer: review of the literature.","volume":"36","author":"Fuccio","year":"2011","journal-title":"Clin Nucl Med"},{"key":"R28-31-20210204","first-page":"54","article-title":"Marzola MC, et al..","volume":"37","author":"Grassetto","year":"2012","journal-title":"FDG PETCT in ovarian cancer: what about treatment response and prognosis Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0b013e31825b2583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:26:42Z","timestamp":1621884402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201208000-00031"}},"subtitle":["Correlation With Histology, Serum CA-125 Assay, and Conventional Radiological Modalities"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e31825b2583","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}